About Careers MedBlog Contact us

Drug for Muscle Wasting Helps Children With Later-onset Disease

by Ramya Rachamanti on April 26, 2019 at 9:35 AM
Font : A-A+

Drug for Muscle Wasting Helps Children With Later-onset Disease

Drug that is effective in treating spinal muscular atrophy (SMA), the rare muscle-wasting disease, early in life could be associated with an improvement in older children, according to a study published in Neurology, the medical journal of the American Academy of Neurology.

Spinal muscular atrophy is a neurodegenerative disease that attacks nerve cells in the spinal cord, leading to muscle weakness. This can affect breathing, swallowing, walking and head control. There are several types of SMA, some of them fatal.


SMA type I is the most common and most severe form of the disease. It starts before the age of six months, with infants never gaining the ability to sit up. The median survival rate is eight to 14 months old.

In babies with SMA type II, symptoms start after six months; they reach the ability to sit and some may be able to stand with support but they are unable to walk. In SMA type III, symptoms start after children are 18 months old; they are able to walk but become progressively weaker and some lose the ability to walk over time.

"This study involved kids up to age 15 years at enrollment with SMA types II and III, and they were followed for approximately three years, so we were excited to see that the drug can show benefit for these older kids too and that the benefit can extend for this period of time," said study author Basil T. Darras, MD, of Boston Children's Hospital and Harvard Medical School and a member of the American Academy of Neurology.

For the study, 28 children with spinal muscular atrophy--11 with type II and 17 with type III--received injections of the drug nusinersen into the spinal canal two to three times over 85 days and then were followed for an additional six months.

The drug is the first and only approved treatment for all types of SMA. It works by increasing the production of a certain protein that is essential for motor neurons in the spinal cord to survive. The phase 1/2a study was open-label, which means that both the researchers and the participants and their families were aware of the drug that they were given.

After that part of the study ended, 24 of the children continued on and received four doses of the drug six months apart in an extension study.

Participants' movement abilities were tested at the beginning of the study, during the study and again six months after the last drug treatment.

"The children's motor function improved, and their disease activity stabilized in ways that were definitely not consistent with the normal history of this disease," Darras said. "One of the children with SMA type II gained the ability to walk independently after about 18 months of treatment and continued to improve during the study. Two of the four children with SMA type III who had lost the ability to walk before the study started regained their ability to walk independently."

In a test of how well participants could perform skills such as sitting without support, rolling onto their side, kneeling, or standing with or without support, the children with SMA type II improved by an average of 10.8 points, where an individual improvement of at least three points was considered meaningful and normally kids with this type of SMA would decline by an average of 1.7 points during the same time period.

On a test of how many meters they could walk in six minutes, the children with SMA type III who were able to walk at the beginning of the study improved by an average of 36 meters a year after starting the treatment, where an individual improvement of at least 30 meters was considered meaningful and normally kids with this type of SMA would decline by an average of 1.5 meters during the same time period. The five children who completed this test at the end of the study improved by an average of 92 meters.

None of the children stopped taking the drug due to side effects.

Limitations of the study included the small number of participants, the open-label design where participants, families and researchers all knew what treatment they were receiving and the lack of control groups within the study. The results do not prove cause and effect between the treatment and the improvements; they only show an association.

Source: Eurekalert


Recommended Reading

Latest Genetics & Stem Cells News

 Stem Cell Treatment Resolves Perianal Fistulas in Crohn's Disease
Can stem cell therapy cure fistula? Yes, treatment with stem cells has had a success rate when used in perianal fistulas due to Crohn's Disease.
First Effective Preclinical Models for Most Common Genetic Cause of Leigh Syndrome
In zebrafish models of SURF1 mitochondrial disease, scientists have discovered drugs to prevent neurological decompensation.
Gene Therapy for Rare Eye Disease
New study advances intravitreal gene therapy platform to develop safe and effective therapies for visual loss in Usher Syndrome, rare disorder.
Autism-associated Mutation: New Insights
The study experiments shed light on a rare example of how autism-associated mutation could altered nuclear dynamics.
How Genomic Variants Could Help Diagnose Rare Genetic Disorders
A genotype-first approach to patient care involves selecting patients with specific genomic variants and then studying their traits and symptoms.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Drug for Muscle Wasting Helps Children With Later-onset Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests